Immunocore Holdings plc ADR (IMCR)
NASDAQ: IMCRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMCR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.36B
- EPS (TTM)
- -$0.64
- Dividend yield
- None
- 52-week range
- 25.61 – 40.72
- Day range
- 25.61 – 26.77
- Volume / Avg
- 546.18K / 450.88K
- Beta
- —
- Shares outstanding
- 51.68M
52-week range
IMCR stock today
Shares of Immunocore (IMCR) finished lower on Nov 20 at $26.41, a drop of 0.83% or $0.22 per share, versus the S&P 500's 3.70% decline. Shares are 35.1% below their 52-week high of $40.72, set on Dec 5, 2025 and 3.1% above the 52-week low of $25.61, near the bottom of the past year's range. IMCR is down 23.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 32.9%.
Immunocore has posted a net loss over the last twelve months (EPS of -$0.64), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Immunocore
Company profileImmunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Bahija Jallal Ph.D.
- Headquarters
- Abingdon
- Employees
- 524
- IPO year
- 2021
- Website
- immunocore.com
Financial highlights
Full financialsIn fiscal 2025, Immunocore generated $400.0 million in revenue, up 29.0% from fiscal 2024, its 4th consecutive year of revenue growth. Immunocore reported a net loss of $35.5 million, compared with a loss of $51.1 million a year earlier. Gross margin was 98.7% (down from 99.1%) and operating margin -11.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $400.02M | $310.20M | $249.43M | $174.36M | $36.48M |
| Growth | +28.95% | +24.37% | +43.05% | +377.91% | — |
| Net income | $-35.51M | $-51.09M | $-55.29M | $-52.54M | $-180.03M |
| EPS (diluted) | $-0.71 | $-1.02 | $-1.13 | $-1.15 | $-4.24 |
Analyst forecast
ForecastConsensus (12 analysts)
buy
Avg. price target
$59.30+124.54%
- Strong buy 2
- Buy 6
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 6, 2026
- EPS actual vs est.
- $-0.28 vs $-0.12
- Surprise
- -133.33%
IMCR news
All IMCR news- Immunocore to present at upcoming investor conferencesGlobeNewswire
- Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanomaGlobeNewswire
- Immunocore reports third quarter financial results and provides a business updateGlobeNewswire
- Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meetingGlobeNewswire
- EU Approves Expanded Use of ABBV's Tepkinly in Follicular LymphomaNasdaqABBV, AMRN, GMAB, IMCR
- FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer TherapyNasdaqIMCR, IBRX, INDV
- ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder CancerNasdaqIMCR, IBRX, INDV
Immunocore peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MESOMesoblast Limited ADR | 10.89 | -2.59% | $1.41B | vs IMCR |
| WWBWindward Bio Group AG | 24.29 | +1.15% | $1.45B | vs IMCR |
| ALVOAlvotech | 4.12 | -3.96% | $1.47B | vs IMCR |
| NVAXNovavax Inc. | 7.47 | -3.24% | $1.23B | vs IMCR |
| RXRXRecursion Pharmaceuticals Inc. Class A | 2.45 | -9.93% | $1.53B | vs IMCR |
| TSHATaysha Gene Therapies Inc. | 3.72 | -1.33% | $1.21B | vs IMCR |
| VIRVir Biotechnology Inc. | 8.39 | -5.41% | $1.56B | vs IMCR |
| VORVor Biopharma Inc. | 19.19 | +3.62% | $1.18B | vs IMCR |
Indexes, lists and sector
Immunocore stock FAQ
What is Immunocore's stock price today?
IMCR last traded at $26.41 as of Nov 20, 4:00 PM EST, down 0.83% on the day. Prices are delayed at least 15 minutes.
Who is Immunocore's CEO?
Dr. Bahija Jallal Ph.D. is the chief executive officer of Immunocore Holdings plc ADR, which has about 524 employees.
What is the IMCR 52-week high?
The 52-week high for IMCR is $40.72 and the 52-week low is $25.61. The stock is currently 35.1% below its high.